WO2023101047A1 - Solution de nettoyage pour lentilles de contact à base de protéase et son procédé de préparation - Google Patents
Solution de nettoyage pour lentilles de contact à base de protéase et son procédé de préparation Download PDFInfo
- Publication number
- WO2023101047A1 WO2023101047A1 PCT/KR2021/018037 KR2021018037W WO2023101047A1 WO 2023101047 A1 WO2023101047 A1 WO 2023101047A1 KR 2021018037 W KR2021018037 W KR 2021018037W WO 2023101047 A1 WO2023101047 A1 WO 2023101047A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protease
- mpc
- cypress
- solution
- extract
- Prior art date
Links
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 65
- 239000004365 Protease Substances 0.000 title claims abstract description 65
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract description 65
- 238000004140 cleaning Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 34
- 239000008213 purified water Substances 0.000 claims abstract description 28
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- CXKOMPKKJHARHG-UHFFFAOYSA-O CC=CC(=O)OCCP(=O)=C(O)C[N+](C)(C)C Chemical compound CC=CC(=O)OCCP(=O)=C(O)C[N+](C)(C)C CXKOMPKKJHARHG-UHFFFAOYSA-O 0.000 claims abstract description 4
- 241000218691 Cupressaceae Species 0.000 claims description 74
- 239000000243 solution Substances 0.000 claims description 68
- 241000208843 Arctium Species 0.000 claims description 38
- 235000003130 Arctium lappa Nutrition 0.000 claims description 38
- 235000008078 Arctium minus Nutrition 0.000 claims description 38
- 239000007864 aqueous solution Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 19
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 11
- 239000003431 cross linking reagent Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 150000003141 primary amines Chemical class 0.000 claims description 4
- 240000007695 Nandina domestica Species 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 238000009736 wetting Methods 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 24
- 239000003921 oil Substances 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 239000000126 substance Substances 0.000 description 14
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 241000228245 Aspergillus niger Species 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 241000224422 Acanthamoeba Species 0.000 description 4
- 241000224489 Amoeba Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000882 contact lens solution Substances 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- -1 methylacryloyloxyethyl phosphoryl Chemical group 0.000 description 4
- 239000005445 natural material Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 2
- 235000003320 Adansonia digitata Nutrition 0.000 description 2
- 244000056971 Adansonia gregorii Species 0.000 description 2
- 235000003319 Adansonia gregorii Nutrition 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- 229920005650 polypropylene glycol diacrylate Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241000224423 Acanthamoeba castellanii Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002111 Eye Abnormalities Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000010639 cypress oil Substances 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- XQYSTRMEVGHJAW-UHFFFAOYSA-L disodium;1-tridecoxytridecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCCOCCCCCCCCCCCCC XQYSTRMEVGHJAW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38618—Protease or amylase in liquid compositions only
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/046—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/36—Organic compounds containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/36—Organic compounds containing phosphorus
- C11D3/364—Organic compounds containing phosphorus containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/382—Vegetable products, e.g. soya meal, wood flour, sawdust
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
Definitions
- the present invention relates to a protease-based contact lens cleaning solution and a manufacturing method thereof, and more particularly, to a protease-based contact that can remarkably improve contact lens wearing comfort by enhancing protein removal and wetting effect by including protease in the contact lens cleaning solution It relates to a lens cleaning liquid and a manufacturing method thereof.
- Contact lenses are lenses mounted on the cornea, which is the front of the eye, and used for purposes such as vision correction, eye treatment and beauty, and are widely used as replacements for eyeglasses.
- these contact lenses are worn for a long time, protein deposits and foreign substances promote the attachment and proliferation of various microorganisms on the surface of the lens, causing keratitis due to bacterial infection.
- keratitis The main cause of keratitis is bacteria parasitic on contact lenses, and Staphylococcus aureus, which is a gram-positive bacterium, and gram-negative bacteria, are known to be the most frequently reported Pseudomonas aeruginosa. For this reason, in order to prevent various eye diseases caused by Gram-positive bacteria and then negative bacteria, various techniques for removing proteins and preventing foreign matter from being attached to the lens surface have been proposed.
- the proposed prior art is a contact lens care formulation and packaging solution (Korean Patent Registration No. 10-1797275), which includes a specific phosphorylcholine analog group-containing monomer unit, a specific (meth)acrylamide derivative unit, A contact lens care formulation and packaging solution comprising a solution containing 0.01 to 2% by weight/volume of a polymer having a weight average molecular weight of 5000 to 2000000 having a specific hydrophobic group-containing monomeric unit in a specific ratio and imparting surface lubricity and amoeba adhesion inhibitory effect
- a contact lens care formulation and packaging solution comprising a solution containing 0.01 to 2% by weight/volume of a polymer having a weight average molecular weight of 5000 to 2000000 having a specific hydrophobic group-containing monomeric unit in a specific ratio and imparting surface lubricity and amoeba adhesion inhibitory effect
- the prior art is prepared in one embodiment and compared to the cleaning solutions prepared according to the conventional contact lens cleaning solution manufacturing method, the surface lubricity and the effect of inhibiting amoeba adhesion are somewhat insufficient, and thus the wearing comfort of the contact lens is excellent There are downsides to not being able to.
- the present invention has been made to solve the above problems, and by including protease in the contact lens cleaning solution, the protein removal and wetting effect are strengthened to significantly improve the wearing comfort of the lens. will be.
- a protease-based contact lens cleaning solution according to an embodiment of the present invention for achieving the above object includes purified water, protease, methylacryloyloxyethyl phosphorylcholine (MPC) and sodium chloride.
- the protease includes a protease cross-linked to a carbomer, wherein a primary amine of the protease is cross-linked to a carboxyl group of the carbomer, and the amine of the protease is further cross-linked by an amine-reactive cross-linking agent.
- the MPC is added by preparing an MPC aqueous solution in which MPC is mixed in a solvent, and then mixing the MPC aqueous solution with the purified water. Purified water is mixed, and the MPC aqueous solution further contains a natural antibacterial agent that prevents the growth of bacteria. manufactured by doing
- the natural antibacterial agent is prepared by adding Nandina domestica Thunb to the cypress extract produced in the manufacturing process of the cypress extract oil, immersing and heating to extract the cypress extract.
- the cypress tree extract is extracted, and then an MPC aqueous solution is prepared.
- MPC aqueous solution preparation step protease addition step of adding protease to the MPC aqueous solution prepared in the MPC aqueous solution preparation step, mixed solution of preparing a mixed solution by mixing sodium chloride and purified water with the MPC aqueous solution to which the protease was added in the protease addition step.
- It includes a manufacturing step, an additive adding step of adding an additive to the mixed solution prepared in the mixed solution preparing step, and a filtration step of filtering the mixed solution added in the additive adding step, and the cypress extract extraction step is the cypress tree extract.
- a solvent is added to and heated, and the water vapor generated by the heating is cooled to separate cypress extract water and cypress extract oil, respectively.
- the MPC aqueous solution preparation step is the step of preparing a cypress extract oil phase solution by dissolving a surfactant in the cypress extract oil extracted in the cypress tree extract extraction step to prepare a cypress extract oil phase solution, dissolving the MPC and a water-soluble crosslinking agent in purified water It includes an MPC solution preparation step of preparing an MPC solution and a mixing step of mixing the cypress extract oil phase solution and the MPC solution to prepare the MPC aqueous solution.
- the MPC solution preparation step further includes a natural antibacterial agent mixing step of mixing a natural antimicrobial agent prepared by adding a mixed solvent to the cypress extract water extracted in the cypress tree extract extraction step and extracting the burdock extract by immersing and heating the burdock root.
- the Namcheon extract is extracted by adding Namcheon to the cypress extract in which the burdock is immersed, followed by immersion and heating.
- protease-based contact lens cleaning solution and method for preparing the same according to the present invention have the following effects.
- protease in the contact lens cleaning solution, there is an effect of significantly improving the wearing comfort of the lens by strengthening the protein removal and wetting effect.
- FIG. 1 is a block diagram showing a method for producing a protease-based contact lens cleaning solution according to a preferred embodiment of the present invention.
- Figure 2 is a block diagram showing the MPC solution preparation step in the protease-based contact lens cleaning solution manufacturing method according to a preferred embodiment of the present invention.
- Figure 3 is a block diagram showing the natural antibacterial agent mixing step in the method for producing a protease-based contact lens cleaning solution according to a preferred embodiment of the present invention.
- first and second may be used to describe various components, but the components should not be limited by the terms. These terms are only used for the purpose of distinguishing one component from another. For example, a first element may be termed a second element, and similarly, a second element may be termed a first element, without departing from the scope of the present invention.
- the protease-based contact lens cleaning solution includes purified water, protease, methylacryloyloxyethyl phosphoryl choline (MPC) and sodium chloride.
- the protease removes proteins on the surface of the contact lens, and includes a protease cross-linked to a carbomer, wherein the primary amine of the protease is cross-linked to a carboxyl group of the carbomer, and the amine of the protease is amine-reactive. It is further cross-linked by a cross-linking agent.
- the protease may further include a stabilizer to prevent a state change or chemical change of the protease.
- a stabilizer to prevent a state change or chemical change of the protease.
- baobab oil, ascorbic acid, and the like may be applied as the stabilizer.
- the purified water is a solvent that occupies most of the volume of the present invention, and it is preferable to use sterilized purified water effective for maintaining a sterilization or antibacterial state in the final product.
- the MPC is methylacryloyloxyethyl phosphoryl choline, a substance in which a methacrylate group and a phosphorylcholine group are combined, and has the same structural formula as human cell membranes and is physically synthesized , which is a hydrophilic substance.
- a protein removal agent or wetting agent on the surface of contact lenses it removes proteins on the surface of contact lenses together with the protease, and provides surface lubricity by suppressing the attachment of amoeba.
- the MPC is preferably mixed in an amount of 0.7 to 1.2 parts by weight based on 100 parts by weight of the purified water.
- protein removal and amoeba attachment inhibition may be reduced, resulting in a decrease in wearing comfort, and when mixed to 1.2 or more, the viscosity of the MPC aqueous solution described below may increase.
- the MPC is added by preparing an aqueous solution in which MPC is mixed in a solvent, and then mixing and adding the MPC aqueous solution to the purified water. Purified water is mixed.
- spherical MPC hydrogel particles are dispersed and formed by the water-soluble crosslinking agent and MPC in the MPC aqueous solution, and the lubricity is improved by simply adding MPC as a conventional technique, protein removal, inhibition of Abema adhesion, and increased moisture.
- the MPC aqueous solution further contains a natural antibacterial agent that prevents the growth of bacteria.
- the natural antibacterial agent is prepared by extracting the burdock extract by immersing and heating the burdock in the cypress extract water generated in the manufacturing process of the cypress extract oil.
- the cypress extract can inhibit the growth of antibiotic-resistant strains, and the burdock extract is a natural substance that inhibits Staphylococcus aureus, a gram-positive bacterium as a bacterium, and maintains antibacterial activity even under acidic conditions of pH. As a compound, it is toxic and replaces antibacterial agents that could not guarantee the safety of the human body.
- the natural antibacterial agent can be extracted by adding Nandina domestica Thunb to the cypress extract in which burdock is immersed, followed by immersion and heating.
- the Namcheon is called Namcheon bamboo leaf, and has a therapeutic effect on whooping cough, hematuria, and bruises. In winter, the green leaves turn red, and in spring they turn blue again.
- the fruit of Namcheon is a round berry, 50 to 100 cm in size, ripens in October and turns red.
- the fruit of Namcheon is called Namcheonsil, Namcheon, or Namcheonjukja in the private sector and is used as a medicine. It is known to be used in the treatment of chronic cough, syphilis, uterine bleeding, asthma, whooping cough, etc., and in one embodiment of the present invention, it has anti-allergic activity, so it can suppress allergic bacteria.
- the sodium chloride (Sodium chloride) is a salt with a chemical formula of NaCl and a molecular weight of 5544, and functions as an isotonic agent, an excipient, a stabilizer, a buffer, a solvent, a viscosity control agent, and a pH control agent. In the present invention, it serves as an isotonic agent that substantially equalizes the osmotic pressure to that of tears and serum.
- the sodium chloride is preferably mixed in an amount of 0.7 to 1 part by weight based on 100 parts by weight of the purified water. If the sodium chloride is out of the range of 0.7 to 1 part by weight, it cannot serve as an isotonic agent because it appears different from the osmotic pressure of tears and serum.
- the biocompatible MPC polymer-based contact lens multifunctional solution manufacturing method includes cypress extract extraction step (S100), MPC aqueous solution preparation step (S200), protease addition step (S300), mixed solution preparation step (S400), additive addition step (S500) and a filtration step (S600).
- cypress tree extract extraction step S100
- cypress tree and cypress oil are extracted, and a solvent is added to the cypress tree, heated, and the water vapor generated by the heating is cooled to separate into cypress tree extract and cypress tree extract oil, respectively do.
- an MPC aqueous solution is prepared after the cypress extract extraction step (S100), and the cypress extract oil phase solution preparation step (S210), MPC solution preparation step (S220), mixing step (S230), and A disinfectant addition step (S240) is included.
- a cypress extract oil phase solution is prepared by dissolving a surfactant in the cypress extract oil.
- the surfactant is Cetyl PEG/PPG-10/1 dimethicone (ABIL EM-90), sorbitan sesquioleate (ARLACEL 83), polyethylene glycol dipoly Hydroxy stearate (Polyethylene glycol dipolyhydroxy stearate (ARLACEL P135)) and the like can be used.
- an MPC solution is prepared by dissolving MPC and a water-soluble crosslinking agent in purified water.
- the MPC and the water-soluble crosslinking agent are preferably mixed in a weight ratio of 1:9.
- the water-soluble crosslinking agent is preferably polypropylene glycol diacrylate (PPG-DA) or polyethylene glycol diacrylate (PEG-DA).
- the MPC solution preparation step (S220) further includes a natural antimicrobial agent mixing step (S221).
- the natural antibacterial agent mixing step 221 is a natural antibacterial agent prepared by adding a mixed solvent to the cypress extract water extracted in the cypress tree extract extraction step (S100) and extracting the burdock extract by immersing and heating burdock or burdock and burdock root. Mix with MPC solution.
- the natural antimicrobial agent mixing step (S221) is a burdock washing and cutting step (S222), a burdock drying step (S223), a burdock roasting step (S224), a soaking step (S225), a base addition step (S226), a mixed solvent addition step ( S227), heating step (S228) and MPC solution mixing step (S229).
- the leaves and stems of burdock are mixed in a weight ratio of 1:3, washed, and cut into sizes within the range of 0.1 mm to 20.0 mm.
- the burdock In the step of drying the burdock (S223), it is dried with hot air having a temperature in the range of 70 to 80 ° C.
- the dried burdock is steamed for 20 to 30 minutes in a vacuum state.
- the immersion step (S225) the soaked burdock is immersed in the cypress extract water extracted in the cypress tree extraction step. At this time, it can be immersed by adding Namcheon to the cypress extract.
- the Namcheon can be immersed in several parts, but preferably any one selected from the leaves, stems and fruits of the Namcheon is immersed.
- the base addition step (S226) 0.1 to 10 parts by weight of a base is added based on 100 parts by weight of the cypress extract.
- the base may be sodium hydroxide (NaOH) or potassium hydroxide (KOH).
- the base increases the extraction yield of flavonoids, which are antibacterial substances, from burdock. If it is less than the above range, the degree of increase in the extraction yield is insignificant, and if it exceeds the above range, antibacterial substances are hydrolyzed, which is not preferable.
- a mixed solvent is added to the cypress extract water in which burdock or burdock and Namcheon are immersed.
- the mixed solvent is purified water, carbon number, and C1 to C4 lower alcohol, polyhydric alcohol, or a mixture thereof.
- the cypress extract water in which the burdock or burdock root and namcheon are immersed in the mixed solvent addition step (S227) is heated, and heated to a temperature within the range of 100 to 150 ° C., so that a natural antibacterial agent is finally prepared.
- the natural antibacterial agent prepared by heating in the heating step (S228) is mixed with the MPC solution.
- the cypress extract oil phase solution and the MPC solution are mixed to prepare an MPC aqueous solution.
- the cypress extract oil phase solution and the MPC solution are mixed in a weight ratio of 1:1 to 8:3. It is desirable to do
- a disinfectant for sterilizing microorganisms, bacteria and organic matter is added to the MPC aqueous solution.
- the disinfectant is any one selected from silicon dioxide, titanium dioxide and nanosilver.
- protease is added to remove proteins on the surface of the contact lens.
- the protease is to remove the protein on the surface of the contact lens, and includes a protease cross-linked to carbomer, wherein the primary amine of the protease is cross-linked to the carboxyl group of the carbomer, and the amine of the protease is Further crosslinked by an amine reactive crosslinker.
- the protease may further include a stabilizer to prevent state change or chemical change.
- the stabilizer is preferably baobab oil, ascorbic acid, etc. are applied.
- a mixed solution is prepared by mixing the MPC aqueous solution, sodium chloride, and purified water, and 0.7 to 1 part by weight of sodium chloride is added to 100 parts by weight of purified water occupying the majority of the volume, and MPC is 0.7 to 1 part by weight.
- a mixed solution is prepared by adding a small amount of the MPC aqueous solution to a weight of 1.2.
- an additive is added to the mixed solution.
- the additive may be selected from among isotonic agents, excipients, stabilizers, buffers, solvents, viscosity control agents and pH control agents and added according to the user's needs.
- the filtration step (S600) foreign substances present in the mixed solution are filtered, and finally, a multifunctional contact lens solution based on biocompatible MPC polymer is prepared.
- Example 1 mixes protease, methylacryloyloxyethyl phosphorylcholine (MPC) and sodium chloride in purified water. Thereafter, the MPC is mixed with a solvent to prepare an MPC aqueous solution, and the MPC aqueous solution is mixed with purified water.
- MPC methylacryloyloxyethyl phosphorylcholine
- the MPC aqueous solution is a mixture of a solution of cypress extract oil in which a surfactant is dissolved and purified water in which MPC and a water-soluble crosslinking agent are dissolved.
- Example 2 Contact lens cleaning solution based on protease containing natural antibacterial agent
- Example 2 the MPC aqueous solution of Example 1 contains a natural antibacterial agent that prevents the growth of bacteria.
- the natural antibacterial agent is prepared by immersing and heating burdock and southern spring in the cypress extract water generated in the production of the cypress extract oil, and extracting the burdock extract and the southern spring extract.
- Comparative Example 1 was a product of Company A, and a multifunctional contact lens solution was prepared by mixing sodium chloride, polyaminopropylbiguanide hydrochloride (PHMB), hyaluronic acid, and additives in purified water.
- PHMB polyaminopropylbiguanide hydrochloride
- Comparative Example 2 was a product of company B, and a multifunctional contact lens solution was prepared by mixing sodium chloride, polyaminopropylbiguanide hydrochloride (PHMB), and chlorhexidine gluconate in purified water.
- PHMB polyaminopropylbiguanide hydrochloride
- Comparative Example 3 a product of C company prepared a multifunctional contact lens solution in which sodium chloride, polyaminopropylbiguanide hydrochloride (PHMB), and tridecyl ether sodium sulfate were mixed in purified water.
- PHMB polyaminopropylbiguanide hydrochloride
- tridecyl ether sodium sulfate tridecyl ether sodium sulfate
- Test Example 1 in order to confirm the safety of Examples 1 and 2 and Comparative Examples 1 to 3, an eye irritation test was performed for a topical toxicity test item in compliance with the toxicity test standards for pharmaceuticals announced by the Food and Drug Administration.
- Test Example 1 9 rabbits (New zealand White 22 ⁇ 05 kg) without eye abnormalities were examined with the naked eye and ophthalmoscope before the test, and 100 ⁇ l of the test substance was instilled into the right eye, and the left eye was compared. For this purpose, the test substance was not instilled.
- Examples 1 and 2 and Comparative Examples 1 to 3 were observed at 1 hour, 1, 2, 3, 4, and 5 days after instillation.
- irritation such as redness and edema of the conjunctiva was slightly stimulated only on the first day in both the non-face wash group and the face wash group. It was confirmed to be irritating, but it was confirmed to be very safe as a non-irritant in fact.
- Comparative Examples 1 to 3 some stimulation appeared to have a higher value than that of Examples, indicating that more stimulation occurred. Therefore, it can be seen that Examples 1 and 2 are superior.
- Test Example 2 measured and compared functional properties such as appearance change, Dia, moisture content, pH, tensile strength and cleaning effect when using contact lenses. Table 2 below shows the results of comparing Examples 1 and 2 and Comparative Examples 1 to 3.
- Example 1 Example 2 Comparative Example 1 Comparative Example 2 Comparative Example 3 change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance No change in appearance Dia(mm) 14.0 13.5 14.1 14.2 14.1 Moisture content % 52 ⁇ 3 54 ⁇ 3 52 ⁇ 3 51 ⁇ 5 50 ⁇ 3 pH 6.82 6.95 7.41 7.09 7.23 tensile strength no change no change no change no change no change no change no change no change no change cleaning effect +++ ++++ ++ +++ ++ ++
- Examples 1 and 2 according to the present invention do not cause a change in the characteristics of the contact lens even when compared with the conventional Comparative Examples 1 to 3 containing biguanide, and in particular, the cleaning effect visible to the naked eye is also compared to the conventional comparative examples. It can be seen that it is more excellent than that and is suitable for use.
- Test Example 3 Comparison of antibacterial activity against Acanthamoeba
- Test Example 3 an antibacterial test was conducted to confirm the antibacterial activity of the protease-based contact lens cleaning solution against Acanthamoeba. The results are shown in Table 3 below.
- Examples 1 and 2 have high antibacterial activity against Acanthamoeba. These results can be said to prove that it effectively inhibits Acanthamoeba while securing safety even when using protease, MPC, and natural substances by replacing polyaminopropylbiguanide hydrochloride (PHMB).
- PHMB polyaminopropylbiguanide hydrochloride
- Example 2 it is proven that it has a significantly superior effect compared to other comparative examples, so that it has a better effect than products currently on the market or conventional technologies.
- Test Example 4 an antimicrobial activity test was performed on Examples 1 and 2 and Comparative Examples 1 to 3, and the antimicrobial activity was tested over a period of time by inoculating organisms into samples of each Example and Comparative Example. The test results are shown in Tables 4 to 8 below.
- Example 1 organisms Viability (cfu/ml) 1 day 7 days 14 days 28 days Escherichia coli 0 0 0 0 Staphylococcus aureus 0 0 0 0 Pseudomonas aeruginosa 0.2 x 10 2 0 0 0 0 Candida Albicans 0.2 x 10 2 0 0 0 Aspergillus niger 0.2 x 10 2 0.2 x 10 2 0 0 0 0
- Example 2 organisms Viability (cfu/ml) 1 day 7 days 14 days 28 days Escherichia coli 0 0 0 0 0 Staphylococcus aureus 0 0 0 0 Pseudomonas aeruginosa 0 0 0 0 0 0 Candida Albicans 0 0 0 0 0 Aspergillus niger 0.1 x 10 2 0.2 x 10 2 0 0 0
- Test Example 5 Storage stability test (whether burdock extract and namcheon extract are contained)
- Examples 1 and 2 and Comparative Examples 1 to 3 were placed in a bottle made of HDPE, sealed, and stored in a thermo-hygrostat at a temperature of 40° C. and a relative humidity of 75%, while comparing the degree of generation of impurities for 8 weeks.
- the content of impurities was measured by adding 0.0375 mol/L of methanol 1-decanesulfonate sodium solution and perchloric acid (600:400:1) mixture to each cleaning solution, thoroughly dissolving it through ultrasonic treatment, and filtering with a 0.45 ⁇ m membrane filter to perform liquid chromatography. It was measured according to the graph method.
- the content of the impurities is shown in Table 9 below.
- Example 1 0.05 0.09 0.06 0.12
- Example 2 ND ND 0.08 0.15 Comparative Example 1 0.12 0.14 0.20 0.31 Comparative Example 2 0.14 0.19 0.26 0.40 Comparative Example 3 0.21 0.26 0.36 0.45
- Example 2 the burdock extract and the Namcheon extract were included by immersing and heating the burdock and Namcheon in the cypress extract produced during the manufacturing process of the Cypress extract oil, and showed a better effect in the storage stability test.
- Example 2 has the advantage of maintaining stability according to pH change and chemical change by the chlorogenic acid contained in the burdock extract.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La présente invention concerne une solution de nettoyage pour lentilles de contact à base de protéase et son procédé de préparation et, plus précisément : une solution de nettoyage pour lentilles de contact à base de protéase qui contient de l'eau purifiée, une protéase, de la méthylacryloyloxyéthyl phosphorylcholine (MPC) et du chlorure de sodium, qui améliore significativement le confort de port côté lentille par renforcement des effets d'élimination des protéines et de mouillage, et qui a un effet antibactérien contre les bactéries infectieuses ; ainsi que son procédé de préparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210170159A KR102694602B1 (ko) | 2021-12-01 | 2021-12-01 | 프로테아제 기반의 콘택트렌즈 세정액 및 이의 제조방법 |
KR10-2021-0170159 | 2021-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023101047A1 true WO2023101047A1 (fr) | 2023-06-08 |
Family
ID=86612412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/018037 WO2023101047A1 (fr) | 2021-12-01 | 2021-12-01 | Solution de nettoyage pour lentilles de contact à base de protéase et son procédé de préparation |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102694602B1 (fr) |
WO (1) | WO2023101047A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000147442A (ja) * | 1998-08-31 | 2000-05-26 | Nof Corp | コンタクトレンズ用処理溶液 |
JP2000241773A (ja) * | 1999-02-22 | 2000-09-08 | Nof Corp | コンタクトレンズ用処理溶液 |
KR20120118040A (ko) * | 2010-01-19 | 2012-10-25 | 바스프 코포레이션 | 스킨 케어에서 사용하기 위한 안정화된 프로테아제 |
KR20140104174A (ko) * | 2013-02-20 | 2014-08-28 | (주)엔보이비젼 | 단백질 흡착 방지 조성물 및 이의 응용 |
KR20150050500A (ko) * | 2013-10-31 | 2015-05-08 | (주)아모레퍼시픽 | Mpc와 수용성 가교제를 이용한 구형 하이드로겔 입자 |
KR101618012B1 (ko) * | 2015-08-31 | 2016-05-04 | 전라남도 | 편백 추출물을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 조성물 |
JP6383893B2 (ja) * | 2016-02-17 | 2018-08-29 | 株式会社シード | 抗アカントアメーバコンタクトレンズ用溶剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN07972A (fr) | 2012-03-02 | 2015-05-01 | Nof Corp | |
EP3855241B1 (fr) * | 2018-09-18 | 2024-01-24 | NOF Corporation | Solution de traitement de lentille de contact |
-
2021
- 2021-12-01 KR KR1020210170159A patent/KR102694602B1/ko active Active
- 2021-12-01 WO PCT/KR2021/018037 patent/WO2023101047A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000147442A (ja) * | 1998-08-31 | 2000-05-26 | Nof Corp | コンタクトレンズ用処理溶液 |
JP2000241773A (ja) * | 1999-02-22 | 2000-09-08 | Nof Corp | コンタクトレンズ用処理溶液 |
KR20120118040A (ko) * | 2010-01-19 | 2012-10-25 | 바스프 코포레이션 | 스킨 케어에서 사용하기 위한 안정화된 프로테아제 |
KR20140104174A (ko) * | 2013-02-20 | 2014-08-28 | (주)엔보이비젼 | 단백질 흡착 방지 조성물 및 이의 응용 |
KR20150050500A (ko) * | 2013-10-31 | 2015-05-08 | (주)아모레퍼시픽 | Mpc와 수용성 가교제를 이용한 구형 하이드로겔 입자 |
KR101618012B1 (ko) * | 2015-08-31 | 2016-05-04 | 전라남도 | 편백 추출물을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 조성물 |
JP6383893B2 (ja) * | 2016-02-17 | 2018-08-29 | 株式会社シード | 抗アカントアメーバコンタクトレンズ用溶剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20230082338A (ko) | 2023-06-08 |
KR102694602B1 (ko) | 2024-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1200094B1 (fr) | Compositions ophtalmiques renfermant des antibiotiques et un composant ains | |
US9044489B2 (en) | Medicinal compositions containing honey | |
RU2448736C1 (ru) | Офтальмологическая композиция с амфотерным поверхностно-активным веществом и гиалуроновой кислотой | |
US5141928A (en) | Ophthalmic medication | |
JP2001526090A (ja) | アミノビグアニド化合物ならびにコンタクトレンズの消毒および医薬組成物の保存におけるその使用。 | |
KR100878053B1 (ko) | 나린진을 함유한 항균 콘택트렌즈 및 그의 제조방법 | |
WO2022075593A1 (fr) | Solution multifonctionnelle à base de polymère mpc biocompatible pour lentilles de contact et son procédé de préparation | |
WO2023101047A1 (fr) | Solution de nettoyage pour lentilles de contact à base de protéase et son procédé de préparation | |
WO2023101046A1 (fr) | Solution pour lentilles de contact à base de mpc et de protéase, et son procédé de préparation | |
EP0323522A1 (fr) | Larme artificielle | |
EP2895161B1 (fr) | Procédé de traitement ou de prévention d'infections oculaires | |
CN108697820B (zh) | 抗棘阿米巴接触镜用溶剂 | |
HU209538B (en) | Set and cleaning composition for treating contactlenses | |
WO2022075594A1 (fr) | Désinfectant pour les mains à base de polymère mpc biocompatible et son procédé de production | |
CN108310442B (zh) | 眼科用组合物 | |
CN116139067A (zh) | 使低浓度、小分子量透明质酸锌形成凝胶的方法、含透明质酸锌的抑菌滴眼凝胶及其制备 | |
KR100804105B1 (ko) | 항균성 미네랄을 함유한 보습 인공 눈물 | |
WO2021091040A1 (fr) | Hydrogel utilisant du chitosane dérivé de champignon, ou des dérivés de celui-ci, et son procédé de production | |
CN117946818A (zh) | 一种含天然活性物质的隐形眼镜保养液及其制备方法及其应用 | |
US20200121712A1 (en) | Agent to be applied to ophthalmic device | |
Ahmed et al. | EFFECTIVENESS OF MULTIPURPOSE CONTACT LENS SOLUTIONS (MPSs) AVAILABLE IN EGYPTIAN MARKET ON MICRO-CONTAMINATION AND BIOFILM FORMATION ON CONTACT LENSES. | |
CN117946822A (zh) | 一种防护型隐形眼镜保养液及其制备方法及其应用 | |
CN117482038A (zh) | 通过多模式策略治疗细菌性角膜炎的抑菌水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21966473 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21966473 Country of ref document: EP Kind code of ref document: A1 |